7月21日晚间,浙江同源康医药股份有限公司(简称“同源康医药”)发布公告,与齐鲁制药围绕肺癌靶向创新药TY-9591(甲磺酸艾多替尼,商品名卡达沙)达成全链条深度战略合作。这场潜在总对价超27亿元的交易,囊括独家商业化授权、原料药产线共建、战略股权认购等。 潜在交易总额超27亿元 根据合作协议,本次合作整体首付款合计7亿元,包括3亿元现金技术授权首付款及齐鲁制药全资投资平台以4亿元等值港元战略...
Source Link7月21日晚间,浙江同源康医药股份有限公司(简称“同源康医药”)发布公告,与齐鲁制药围绕肺癌靶向创新药TY-9591(甲磺酸艾多替尼,商品名卡达沙)达成全链条深度战略合作。这场潜在总对价超27亿元的交易,囊括独家商业化授权、原料药产线共建、战略股权认购等。 潜在交易总额超27亿元 根据合作协议,本次合作整体首付款合计7亿元,包括3亿元现金技术授权首付款及齐鲁制药全资投资平台以4亿元等值港元战略...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.